GlassScriptPhysician profile
Mark T Inda
NPI 1659877678
$4,637.62
in general payments reported to CMS, 2019-2025
27 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $1,415 · 2023: $1,349 · 2024: $804 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,491.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $354.35 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $329.35 | 2022-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $315.81 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $310.77 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $307.39 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.59 | 2021-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $161.65 | 2022 | |
| Abbvie INC. | $131.20 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $130.58 | 2022-2023 | Quviviq |
| Amgen INC. | $122.74 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $120.43 | 2021-2025 | Breztri, Fasenra, Airsupra |
| Sanofi-Aventis U.S. LLC | $94.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $82.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.36 | 2021-2023 | Trulance, Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $65.47 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $54.34 | 2022-2023 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $48.43 | 2021 | |
| Boston Scientific Corporation | $45.49 | 2025 | Ams 700 |
| Eisai INC. | $45.47 | 2021 | |
| Gilead Sciences, INC. | $33.32 | 2025 | |
| Abbott Laboratories | $24.10 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $17.77 | 2021 | |
| Amarin Pharma, INC. | $15.07 | 2022 | |
| Axsome Therapeutics, INC. | $14.73 | 2025 | Symbravo |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Inda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.